UroGen Pharma Ltd. reiterated earnings guidance for the full year 2023. For the year, company expects net product revenues from JELMYTO to be in the range of $76 million to $86 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.08 USD | -0.34% | -3.86% | -12.77% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.77% | 473M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.69% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023